Get started

Breakout

Tesla - Possibility Of A BreakoutNASDAQ:TSLA can break out soon: Over the past two weeks we saw an incredible stock market rally and also Tesla completely reversed the flash crash which we saw in the beginning of August. It is still quite possible that Tesla will break out of the long term triangle and immediately head back to the previous highs. Levels to watch: $230, $400 Click chart above to see the detailed analysis👆🏻 Keep your long term vision, Philip (BasicTrading)
NASDAQ:TSLALong
by basictradingtv
IOLCP Showing Change in Structure can go towards 52 Week HighNSE:IOLCP ...................................................................................................................... ...................................................................................................................... The Company’s turnover increased to ₹ 2,133 crore in FY24 from ₹ 983 crore in FY18 at a CAGR of 13.77% ...................................................................................................................... ...................................................................................................................... The share of regulated market sale has increased to ₹ 300 crore in FY24 from ₹100 crore in FY18 ...................................................................................................................... ...................................................................................................................... Increased contribution of non-Ibuprofen drugs from ₹35 crore in FY18 to ₹431 crore in FY24, showing a steady upward trend over the years ...................................................................................................................... ...................................................................................................................... Added more than 10 products since 2017 in APIs and chemical segments. The Company has recently commenced a new plant of Acetic Anhydride ...................................................................................................................... ...................................................................................................................... • The Indian API market is expected to grow at a CAGR of 13.7% over the four years. • India hosts 500 API manufacturers, contributing approximately 8% to the global API Industry. • As the largest supplier of generic medicines, India manufactures around 60,000 different generic brands across 60 therapeutic categories. • In FY24 India saw a 4.12% increase in the total imports of bulk drugs and intermediates, amounting to ₹ 37,721.88 crore, compared to ₹ 36,229.15 crore in FY23. • Indian medicines are preferred worldwide due to their combination of low price and high quality, earning India the title of "pharmacy of the world." ...................................................................................................................... ...................................................................................................................... Positive factors • Strongly improving operating performance, resulting in growth of more than 15% in total operating income and sustained EBIDTA margin of more than 20%, on a sustained. • Diversifying product portfolio and reducing dependency on its main product Ibuprofen and ethyl acetate to below 65% in the overall revenue. • Improving total debt to gross cash accruals (TD/GCA) and TD to profit before interest, lease rentals, depreciation, and taxation (TD/PBILDT) to below unity. ...................................................................................................................... ...................................................................................................................... Established market position and diversified product offering The company was incorporated, 1986 with the commencement of business in chemical segment. In 2000, the company started production of Ibuprofen. IOLCPL is one of the largest manufacturers of Ibuprofen with significant global share and the company is backward integrated for manufacturing Ibuprofen. IOLCPL has a market presence across more than 50 countries with sales contribution from exports forming around 28% of total sales in FY24 (PY: 29%). The company’s overseas customers are spread across Switzerland, Bangladesh, Spain, Indonesia, Hungary, United Kingdom, Nepal, China, Turkey and Japan, among others. The company is one of the largest manufacturers of Ibuprofen (capacity of 12000 MTPA) and has the second largest manufacturing capacity (12000MTPA) for Iso Butyl Benzene (key raw material for Ibuprofen)
NSE:IOLCPLong
by iism-ExpertTrading
FIEMIND Turned ON its Marubozu Headlights At ALL TIME HIGH ZONE NSE:FIEMIND GOVT. APPROVED R&D CENTRE • FIEM’s state of the art R&D Centre offers its clients design and development capabilities in Automotive Lighting & Signalling Equipments and Rear View Mirrors which meet the specifications of the clients requirements. • Government of India, Ministry of Science and Technology, Department of Science and Industrial Research has accorded Recognition to Company’s in-house R&D Unit situated at Rai Industrial Estate, Sonepat. • The Company’s R&D Centre is established with modern infrastructure, state-of-the-art technology, equipped with latest software, qualified and experienced manpower. • FIEM’s in-house R&D Centre has various kinds of testing facilities such as Product Testing, Photometry Testing, Environmental Testing, Thermal Tests, Electronic Test, Vibration Test, Chemical Test, Mechanical Tests etc. • Photometry Laboratory of the Company is NABL Accredited. • Some examples of R&D conducted by company: • In-house design and development of Railway IPIS (Integrated Passenger Information Systems with LED Display) • In-house design and development for four wheeler LED Rear combination, LED direction indicator light etc. • Advantages of in-house R&D unit: • Diversified and large portfolio of lighting products developed. • New generation LED technology in automotive and home lighting segments developed. • Reduction in development time and cost savings to clients. Company is almost debt free. Company has delivered good profit growth of 24.4% CAGR over last 5 years Company has been maintaining a healthy dividend payout of 29.3%
NSE:FIEMINDLong
by iism-ExpertTrading
AUCTION ANALYSIS (breakout)🔮 #AUCTION Analysis - Breakout 🚀🚀 💲💲 In daily time-frame,Falling Wedge Pattern is forming and trying to breakout the pattern ✅ Right now we could see a breakout and retest in #AUCTION. After that we would expect a bullish movement in #AUCTION🚀 💸Current Price -- $17.27 📈Target Price   --  $35.20   ⁉️ What to do? - We have marked crucial levels in the chart . We can trade according to the chart and make some profits. 🚀💸 #AUCTION  #Cryptocurrency #Breakout #DYOR
Long
by ZEUS_Market_Alerts